Antioxidants & Redox Signaling (ARS) is the leading journal dedicated to the understanding of redox principles governing health and disease. This Journal provides and explores key aspects of the important and expanding world of redox-based therapeutics—genetic, pharmacological, and nutritional. Cutting-edge research focuses on structural biology, stem cells, regenerative medicine, epigenetics, imaging, clinical outcomes, and preventive and therapeutic nutrition, among other areas.
ARS has expanded to create two unique foci within one journal: ARS Discovery and ARS Therapeutics. ARS Discovery (24 issues) will publish the highest-caliber breakthroughs in basic and applied research. ARS Therapeutics (12 issues) will be the first publication of its kind that will help enhance the entire field of redox biology by showcasing the potential of redox sciences to change health outcomes.
ARS coverage includes:
- ROS/RNS as messengers
- Gaseous signal transducers
- Hypoxia and tissue oxygenation
- Prokaryotic systems
- Lessons from plant biology
ARS is under the editorial leadership of Editor-in-Chief Chandan K. Sen, Wexner Medical Center at The Ohio State University and other leading investigators. View the entire editorial board.
Audience: Cell biologists, molecular biologists, biochemists, medical researchers, and nutritionists, among others.
ARS provides "Instant Online" publication 72 hours after acceptance.
Average time to first decision: 18 days
Average time to triage decision: 48 hours
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.